Polycystic ovary syndrom. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: In case group metformin 1000 mg/day Cabergoline, 0.5 ml tablet one/week for 4 months was given. Intervention 2: In control group metformin 1000 mg/day and cabergoline pelacebo weekly f
Treatment - Drugs
Placebo
In case group metformin 1000 mg/day Cabergoline, 0.5 ml tablet one/week for 4 months was given.
In control group metformin 1000 mg/day and cabergoline pelacebo weekly for 4 months were given.
Sponsors
Shahid sdoughi university of medical sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: 110 PCOS women with increased serum prolactin concentration [1.5 fold more than normal level (>37.5ng/ml)]; between 18-35 years old, who referred to endocrinology clinic of Khatamal Anbiaa Cilinic, Shahid Sadoughi University of Medical Sciences, were examined for other causes of increased prolactin levels such as TSH test, hypophis MRI for detection of prolactinema and other disorders or tumors that can increase prolactin, and then women who had diagnosed as PCOS according to the latest AES standards enrolled in the study. Patients who had other endocrine disorders (such as thyroid disorders), history of cardiovascular disease, history of using the increasing prolactin drugs, women who wanted to be pregnant, and who couldn’t tolerate the cabergoline were excluded from the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Menstural irregularity. Timepoint: at the beggining of study and 4 months after intervention. Method of measurement: standard questionniare.;Serum testosteron. Timepoint: at the beggining of study and 4 months after intervention. Method of measurement: enzyme-linked radio immune sorbent assay (ELISA).;Serum DHEAS. Timepoint: at the beggining of study and 4 months after intervention. Method of measurement: enzyme-linked radio immune sorbent assay (ELISA).;Serum prolactin. Timepoint: at the beggining of study and 4 months after intervention. Method of measurement: enzyme-linked radio immune sorbent assay (ELISA). | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: at the beggining of study and 4 months after intervention. Method of measurement: With SECA scale per kilogram. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Akram Jowkar
Shahid sdoughi university of medical sciences
Outcome results
None listed